

## Aktuell zur Diagnostik und Therapie der neonatalen Alloimmunthrombozytopenie

1. Winkelhorst D, Oepkes D. Foetal and neonatal alloimmune thrombocytopenia. *Best Pract Res Clin Obstet Gynaecol.* 2019; 58: 15-27.
2. de Vos TW, Winkelhorst D, de Haas M, Lopriore E, Oepkes D. Epidemiology and management of fetal and neonatal alloimmune thrombocytopenia. *Transfus Apher Sci.* 2019: 102704.
3. Kjeldsen-Kragh J. Foetal and neonatal alloimmune thrombocytopenia-A rare, potentially serious and often underdiagnosed bleeding condition. *Transfus Apher Sci.* 2019: 102703.
4. Kamphuis MM, Paridaans N, Porcelijn L, De Haas M, Van Der Schoot CE, Brand A, Bonsel GJ, Oepkes D. Screening in pregnancy for fetal or neonatal alloimmune thrombocytopenia: systematic review. *BJOG.* 2010; 117: 1335-43.
5. Leach JL, Sedmak DD, Osborne JM, Rahill B, Lairmore MD, Anderson CL. Isolation from human placenta of the IgG transporter, FcRn, and localization to the syncytiotrophoblast: implications for maternal-fetal antibody transport. *J Immunol.* 1996; 157: 3317-22.
6. Kjeldsen-Kragh J, Ahlen MT. Foetal and neonatal alloimmune thrombocytopenia - The role of the HLA-DRB3\*01:01 allele for HPA-1a-immunisation and foetal/neonatal outcome. *Transfus Apher Sci.* 2019: 102707.
7. Anani Sarab G, Moss M, Barker RN, Urbaniak SJ. Naturally processed peptides spanning the HPA-1a polymorphism are efficiently generated and displayed from platelet glycoprotein by HLA-DRB3\*0101-positive antigen-presenting cells. *Blood.* 2009; 114: 1954-7.
8. Santoso S, Wihadmadyatami H, Bakchoul T, Werth S, Al-Fakhri N, Bein G, Kiefel V, Zhu J, Newman PJ, Bayat B, Sachs UJ. Antiendothelial alphavbeta3 Antibodies Are a Major Cause of Intracranial Bleeding in Fetal/Neonatal Alloimmune Thrombocytopenia. *Arterioscler Thromb Vasc Biol.* 2016; 36: 1517-24.
9. Bakchoul T, Kubiak S, Krautwurst A, Roderfeld M, Siebert HC, Bein G, Sachs UJ, Santoso S. Low-avidity anti-HPA-1a alloantibodies are capable of antigen-positive platelet destruction in the NOD/SCID mouse model of alloimmune thrombocytopenia. *Transfusion.* 2011; 51: 2455-61.
10. Peterson JA, Kanack A, Nayak D, Bougie DW, McFarland JG, Curtis BR, Aster RH. Prevalence and clinical significance of low-avidity HPA-1a antibodies in women exposed to HPA-1a during pregnancy. *Transfusion.* 2013; 53: 1309-18.
11. Kjeldsen-Kragh J, Killie MK, Tomter G, Golebiowska E, Randen I, Hauge R, Aune B, Oian P, Dahl LB, Pirhonen J, Lindeman R, Husby H, Haugen G, Gronn M, Skogen B, Husebekk A. A screening and intervention program aimed to reduce mortality and serious morbidity associated with severe neonatal alloimmune thrombocytopenia. *Blood.* 2007; 110: 833-9.
12. Davoren A, Curtis BR, Aster RH, McFarland JG. Human platelet antigen-specific alloantibodies implicated in 1162 cases of neonatal alloimmune thrombocytopenia. *Transfusion.* 2004; 44: 1220-5.
13. Panzer S, Auerbach L, Cechova E, Fischer G, Holensteiner A, Kitl EM, Mayr WR, Putz M, Wagenbichler P, Walchshofer S. Maternal alloimmunization against fetal platelet antigens: a prospective study. *Br J Haematol.* 1995; 90: 655-60.
14. Harrison CR, Curtis BR, McFarland JG, Huff RW, Aster RH. Severe neonatal alloimmune thrombocytopenia caused by antibodies to human platelet antigen 3a (Baka) detectable only in whole platelet assays. *Transfusion.* 2003; 43: 1398-402.
15. Sachs UJ, Kiefel V, Kroll H, Bein G, Santoso S. Report on the 15th International Society of Blood Transfusion platelet immunology workshop. *Vox Sang.* 2012; 103: 343-51.
16. Sachs UJ, Wienzek-Lischka S, Duong Y, Qiu D, Hinrichs W, Cooper N, Santoso S, Bayat B, Bein G. Maternal antibodies against paternal class I human leukocyte antigens are not associated with foetal and neonatal alloimmune thrombocytopenia. *Br J Haematol.* 2020.
17. Mueller-Eckhardt C, Kiefel V, Grubert A, Kroll H, Weisheit M, Schmidt S, Mueller-Eckhardt G, Santoso S. 348 cases of suspected neonatal alloimmune thrombocytopenia. *Lancet.* 1989; 1: 363-6.
18. Kiefel V, Santoso S, Weisheit M, Mueller-Eckhardt C. Monoclonal antibody--specific immobilization of platelet antigens (MAIPA): a new tool for the identification of platelet-reactive antibodies. *Blood.* 1987; 70: 1722-6.
19. Kjaer M, Bertrand G, Bakchoul T, Massey E, Baker JM, Lieberman L, Tanael S, Greinacher A, Murphy MF, Arnold DM, Baidya S, Bussel J, Hume H, Kaplan C, Oepkes D, Ryan G, Savoia H, Shehata N, Kjeldsen-Kragh J, International Collaboration for Transfusion Medicine G. Maternal HPA-1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. *Vox Sang.* 2019; 114: 79-94.
20. Socher I, Zwingel C, Santoso S, Kroll H. Heterogeneity of HPA-3 alloantibodies: consequences for the diagnosis of alloimmune thrombocytopenic syndromes. *Transfusion.* 2008; 48: 463-72.
21. Ertel K, Al-Tawil M, Santoso S, Kroll H. Relevance of the HPA-15 (Gov) polymorphism on CD109 in alloimmune thrombocytopenic syndromes. *Transfusion.* 2005; 45: 366-73.

22. Petermann R, Bakchoul T, Curtis BR, Mullier F, Miyata S, Arnold DM, Subcommittee on Platelet I. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. *J Thromb Haemost*. 2018; 16: 2526-9.
23. Winkelhorst D, Oostweegel M, Porcelijn L, Middelburg RA, Zwaginga JJ, Oepkes D, van der Bom JG, de Haas M, Lopriore E. Treatment and outcomes of fetal/neonatal alloimmune thrombocytopenia: a nationwide cohort study in newly detected cases. *Br J Haematol*. 2019; 184: 1026-9.
24. Tiller H, Ahlen MT, Akkok CA, Husebekk A. Fetal and neonatal alloimmune thrombocytopenia - The Norwegian management model. *Transfus Apher Sci*. 2019: 102711.
25. Lieberman L, Greinacher A, Murphy MF, Bussel J, Bakchoul T, Corke S, Kjaer M, Kjeldsen-Kragh J, Bertrand G, Oepkes D, Baker JM, Hume H, Massey E, Kaplan C, Arnold DM, Baidya S, Ryan G, Savoia H, Landry D, Shehata N, et al. Fetal and neonatal alloimmune thrombocytopenia: recommendations for evidence-based practice, an international approach. *Br J Haematol*. 2019; 185: 549-62.
26. Baker JM, Shehata N, Bussel J, Murphy MF, Greinacher A, Bakchoul T, Massey E, Lieberman L, Landry D, Tanael S, Arnold DM, Baidya S, Bertrand G, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Savoia H, Ryan G, Hume H, et al. Postnatal intervention for the treatment of FNAIT: a systematic review. *J Perinatol*. 2019; 39: 1329-39.
27. Bakchoul T, Bassler D, Heckmann M, Thiele T, Kiefel V, Gross I, Arnold DM, DiTomasso J, Smith JW, Paes B, Greinacher A. Management of infants born with severe neonatal alloimmune thrombocytopenia: the role of platelet transfusions and intravenous immunoglobulin. *Transfusion*. 2014; 54: 640-5.
28. Regan F, Lees CC, Jones B, Nicolaides KH, Wimalasundera RC, Mijovic A, Royal College of O, Gynaecologists. Prenatal Management of Pregnancies at Risk of Fetal Neonatal Alloimmune Thrombocytopenia (FNAIT): Scientific Impact Paper No. 61. *BJOG*. 2019; 126: e173-e85.
29. Winkelhorst D, Murphy MF, Greinacher A, Shehata N, Bakchoul T, Massey E, Baker J, Lieberman L, Tanael S, Hume H, Arnold DM, Baidya S, Bertrand G, Bussel J, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Ryan G. Antenatal management in fetal and neonatal alloimmune thrombocytopenia: a systematic review. *Blood*. 2017; 129: 1538-47.
30. Wabnitz H, Khan R, Lazarus AH. The use of IVIg in fetal and neonatal alloimmune thrombocytopenia- Principles and mechanisms. *Transfus Apher Sci*. 2019: 102710.